TCRX
NASDAQTScan Therapeutics Inc.
Price$0.24-0.00 (-1.08%)
01:45 PM06:30 PM
News · 26 weeks28-25%
2026-04-192026-10-11
Mix1290d
- SEC Filings6(50%)
- Other3(25%)
- Insider2(17%)
- Analyst1(8%)
Latest news
25 items- INSIDERChief Executive Officer Macbeath Gavin was granted 1,000,000 units of Voting Common Stock, increasing direct ownership by 2,009% to 1,049,767 units (SEC Form 4)4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- INSIDEROfficer Zdraveski Zoran was granted 300,000 units of Voting Common Stock, increasing direct ownership by 6,361% to 304,716 units (SEC Form 4)4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- SECSEC Form 8-K filed by TScan Therapeutics Inc.8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- SECSEC Form 8-K filed by TScan Therapeutics Inc.8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- ANALYSTTScan Therapeutics downgraded by H.C. Wainwright with a new price targetH.C. Wainwright downgraded TScan Therapeutics from Buy to Neutral and set a new price target of $1.00
- SECTScan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- PRTScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid TumorsAdvances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1 ALLOHA™ study; 100% (13/13) patients currently being tracked show complete donor chimerism Pauses further enrollment in Phase 3 ALLOHA-2™ study of TSC-101 due to insufficient capital; allowing data to mature and actively seeking collaboration partners Workforce reduction of approximately 75% and strategic reorganization focuses resources on solid tumors and extends runway into Q4 2027 Company to host webcast today, September 2, at 8:30 a.m. ET WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) --
- SECSEC Form 8-K filed by TScan Therapeutics Inc.8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by TScan Therapeutics Inc.SCHEDULE 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)
- SECSEC Form 10-Q filed by TScan Therapeutics Inc.10-Q - TScan Therapeutics, Inc. (0001783328) (Filer)
- SECTScan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- PRTScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateFirst patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash and cash equivalents fund operations into the second quarter of 2027 WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months ended June 30, 2026, and provided a corporate update. "This is a transformative time for TScan w
- PRTScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceWALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026 at 11:30 a.m. Eastern Time. A webcast of the fireside chat will be available on the "Events and Presentations" section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.
- SECTScan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- PRTScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101 TSC-101 continues to be well-tolerated Company remains on track to enroll their first patient in the Phase 3 ALLOHA-2™ study of TSC-101 this month Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., today, June 22, at 8:30 a.m. ET WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today presen
- PRCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic MalignanciesCollaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan's lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to commercialization Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced an agreement to evaluate automated clinical manufacturing of TSC-101, TScan's lead TCR-T therapy candidate for patients with acute myeloid leukemia (AML) and myelodysplastic syndr
- INSIDERSEC Form 4 filed by Director Baker Bros. Advisors Lp4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- INSIDERSEC Form 4 filed by Director Nicholson Garry A4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- INSIDERSEC Form 4 filed by Director Woods Keith4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- SECTScan Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- INSIDERSEC Form 4 filed by Director Gruia Gabriela4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- INSIDERSEC Form 4 filed by Director Dorton Katina4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- INSIDERSEC Form 4 filed by Director Klencke Barbara4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by TScan Therapeutics Inc.SCHEDULE 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)
- SECSEC Form 10-Q filed by TScan Therapeutics Inc.10-Q - TScan Therapeutics, Inc. (0001783328) (Filer)
TCRX FAQ
7 questionsWhat does TScan Therapeutics Inc. do?
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to...Where does TCRX stock trade?
TScan Therapeutics Inc. (TCRX) is listed on NASDAQ.What sector and industry is TCRX in?
TScan Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did TScan Therapeutics Inc. go public?
TScan Therapeutics Inc. (TCRX) completed its IPO in 2021.What are analysts saying about TCRX?
TScan Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $100.00 price target on 2026-09-08.What companies are similar to TCRX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare TCRX side-by-side with any of them on Quantisnow.How can I track TCRX on Quantisnow?
Quantisnow aggregates TScan Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TCRX to receive live email and push alerts on every new disclosure.